

12th November, 2020

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Further to our letter dated 4th November, 2020, we would like to inform that the Board of Directors of the Company at its meeting held today ie; 12th November, 2020 at 09.00 P.M and concluded at 09.45 P.M., have approved the Un-Audited Financial Results for the quarter and half year ended 30th September, 2020.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-Audited Consolidated Financial Results for the Quarter ended 30th September, 2020.
2. Un-Audited Standalone Financial Results for the quarter ended 30th September, 2020.
3. Auditors' Report on the Standalone and Consolidated Financial Results.

We hereby declare that the Statutory Auditors of the company have issued an unmodified opinion on the Financial results for the Quarter ended 30th September, 2020.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **DECIPHER LABS LIMITED**



Kumar Raghavan
**COMPANY SECRETARY &
COMPLIANCE OFFICER**



DECIPHER LABS LIMITED (CIN CL23280TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@combatdrugs.in / info@decipherlabs.in , Ph: 040-48536100

Unaudited Consolidated Financial Results For the Quarter and Half Year ended 30 September 2020

Particulars	All amounts in ₹ Lakhs, unless otherwise stated					
	Quarter ended			Half Year ended		Year ended
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	1,351.15	1422.17	123.04	2773.32	267.33	2398.65
II. Other income	9.80	17.46	0.75	27.26	0.76	27.29
III. Total revenue (I + II)	1,360.95	1439.63	123.79	2800.58	268.09	2425.94
IV. Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock-in-Trade	11.40	-	16.80	11.40	61.85	61.85
Changes in inventories of finished goods and stock in trade	0.30	1.31	(0.01)	1.61	0.28	0.28
Depreciation and Amortisation	19.83	20.19	21.96	40.02	22.02	55.61
Employee benefits expense	1,146.21	1297.32	65.89	2443.53	126.21	1,957.20
Finance Charges	33.03	37.47	12.64	70.50	12.64	72.15
Other expenses	104.86	53.43	4.75	158.29	32.40	132.23
Total expenses	1,315.63	1409.73	122.03	2725.35	255.40	2,279.32
V. Profit/(Loss) before tax (III - IV)	45.32	29.90	1.76	75.23	12.69	146.62
VI. Tax expense:						
(1) Current tax	14.76	10.19	(0.32)	24.95	2.30	40.98
(2) Deferred tax	(0.35)	(0.75)	(3.04)	(1.10)	(3.04)	(4.46)
VII. Profit/(Loss) for the period (V-VI)	30.93	20.45	5.12	51.38	13.43	110.10
VIII. Other comprehensive income						
i) Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of a foreign Subsidiary	(83.04)	55.21	(0.10)	(27.83)	(0.03)	49.65
IX. Total comprehensive income for the year	(52.11)	75.66	5.02	23.55	13.40	159.75
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	1010.00	800.00	1010.00	800.00	1,010.00
X. Earning per equity share						
(1) Basic	0.31	0.20	0.06	0.51	0.17	0.11
(2) Diluted	0.31	0.20	0.06	0.51	0.17	0.11

Notes

1) The operations of the Company relate to two segments viz., Manufacturing and trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Half Year ended		Year ended
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and trading of Pharmaceutical drugs	28.97	1.40	99.57	30.37	99.57	78.25
b) Consultancy Services	1304.73	1438.23	167.77	2742.96	167.76	2347.68
Total Sales	1333.70	1439.63	267.34	2773.33	267.33	2425.93
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	1333.70	1439.63	267.34	2773.33	267.33	2425.93
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and trading of Pharmaceutical drugs	1.53	0.06	12.31	1.59	12.30	7.06
b) Consultancy Services	76.83	67.30	13.04	144.13	13.04	211.71
Total	78.36	67.36	25.35	145.72	25.34	218.77
Less: Interest	33.03	37.47	-	70.50	-	72.15
Total Profit before tax	45.33	29.88	25.35	75.22	25.34	146.62
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	8.07	323.32	309.33	331.39	309.33	323.33
b) Consultancy Services	33.57	2854.61	286.55	2888.18	286.55	3214.85
Total Assets	41.64	3177.93	595.88	3219.58	595.88	3538.18
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	(0.08)	43.87	81.00	43.79	81.00	45.99
b) Consultancy Services	38.35	1852.07	253.51	1890.42	253.51	2236.12
Total Liabilities	38.26	1895.94	334.51	1934.20	334.51	2282.11

2) The above results for the quarter and half year ended 30 September 2020 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12.11.2020. The Statutory Auditors carried out limited review and have expressed an unmodified opinion

3) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

4) The above results include results of wholly owned subsidiaries

- Decipher Software Solutions LLC, USA
- ICP Solutions Private Limited, India

5) The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6) The Group has adopted Ind AS 116, effective April 1, 2019 and applied the standard to its leases, retrospectively with the cumulative effect of initially applying the standard, recognised on the date of initial application (1st April 2019). Accordingly, the company has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on 1st April 2019. The Company has adopted Ind AS 116 using the cumulative effect method of transitioning.

7) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 12.11.2020

Decipher Labs Limited (Formerly known as Combat Drugs Limited) (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor, Plot No.94, Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@combatdrugs.in / info@decipherlabs.in , Ph: 040-48536100

Consolidated Statement of Asset and Liabilities

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	As at 30 September 2020	As at 31 March 2020
	Unaudited	Audited
I. ASSETS		
Non-current Assets		
(a) Property, Plant and Equipment	39.51	23.16
(b) Right to use assets	141.85	163.67
(c) Deferred tax asset (net)	5.67	4.55
(d) Goodwill	288.65	311.35
(d) Financial assets		
Other financial asset	757.37	699.47
(e) Other non current assets	4.24	68.22
Current Assets		
(a) Inventories	30.26	31.87
(b) Financial assets		
(i) Trade receivables	1,262.09	1,461.77
(ii) Cash and cash equivalents	37.59	146.84
(iii) Other Financial Asset	-	346.30
(c) Other current assets	652.35	280.98
TOTAL ASSETS	3,219.58	3,538.18
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	266.05	246.05
Liabilities		
Non-Current Liabilities		
(a) Financial liabilities		
(i) Lease Liabilities	126.64	147.82
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	151.95	943.84
(ii) Lease Liability	40.20	36.00
(ii) Trade payables		
a) Total outstanding dues of Micro enterprises and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro enterprises and small enterprises	478.13	719.97
(iii) Other Financial liabilities	1,043.81	383.59
(b) Other current liabilities	45.30	10.19
(c) Current Tax Liabilities (net)	57.50	40.72
TOTAL EQUITY AND LIABILITIES	3,219.58	3,538.18



For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

Place: Hyderabad

Date: 12.11.2020

Decipher Labs Limited (Formerly known as Combat Drugs Limited)
(CIN CL23230TG1986PLC006781)
Regd.off: 4th Floor, Plot No.94, Sagar Society,
Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.combatdrugs.in, email: info@combatdrugs.in, Ph: 040-48536100
Consolidated Cash Flow Statement

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	30 September 2020	31 March 2020
Cash flow from operating activities		
Profit before tax	75.22	146.61
Adjustments for : operation	(27.83)	49.65
Depreciation	40.02	55.61
Finance costs	70.50	72.15
Pre paid Rent	(0.48)	(0.48)
Lease Prepaid Rent amortization IND AS	0.61	-
Operating Profit before Working Capital Changes		
Changes in operating assets and liabilities		
(Increase) / Decrease in Trade Receivables	199.68	(1,116.10)
(Increase) / Decrease in Inventories	1.61	0.28
(Increase) / Decrease in Other Assets	(18.99)	(1,480.61)
Increase / (Decrease) in Trade Payable	(241.84)	406.57
Increase / (Decrease) in Goodwill	-	-
Increase / (Decrease) in Other Liabilities	684.55	348.33
Cash Generated from Operations	783.06	(1,517.99)
Income taxes paid	-	-
Net cash inflow (outflow) from operating activities	783.06	(1,517.99)
Net cash inflow (outflow) from investing activities		
Purchase of Fixed assets	(12.97)	(24.17)
Proceeds from Sale of Investments in Subsidiary	-	3.56
Adjustment on account of sale of Investment in subsidiary	-	8.28
Net cash inflow (outflow) from investing activities	(12.97)	(12.33)
Cash flow from financing activities		
Proceeds/(repayment) of borrowings	(791.89)	923.76
Increase in Share Capital and Security Premium*	-	840.00
Finance costs	(59.86)	(72.15)
Payment for lease liabilities	(27.60)	(55.51)
Net cash inflow (outflow) from financing activities	(879.35)	1,636.10
Net increase (Decrease) in cash and cash equivalents	(109.26)	105.79
Cash and Cash equivalents at the beginning of the financial Year	146.85	29.97
Cash and Cash equivalents *	-	11.09
Cash and Cash equivalents at the end of the Year	37.59	146.85



Place: Hyderabad
Date: 12.11.2020

For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015**

**Review Report to
The Board of Directors
Decipher Labs Limited (Formerly known as Combat Drugs Limited)**


1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and half year ended 30th September, 2020 ("the Statement"), being submitted by the Holding pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following subsidiaries:

Decipher Software Solutions LLC, USA
ICP Solutions Private Limited, India

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of




the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of one subsidiary, Decipher Software Solutions LLC, USA included in the consolidated unaudited financial results whose interim financial results reflect total assets of Rs. 2676.98 Lakhs as at as at 30th September, 2020, total revenues of Rs. 1218.27 lakhs and Rs. 2526.94 lakhs, total net profit after tax of Rs. 19.14 lakhs and Rs. 26.97 lakhs, total comprehensive Income of Rs. 19.14 lakhs and Rs. 26.97 lakhs for the quarter ended 30th September, 2020 and for the period from 1st April, 2020 to 30th September, 2020 respectively and net cash outflows of Rs. 89.47 Lakhs for the period from 1st April, 2020 to 30th September, 2020 as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of this subsidiary is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above


Our conclusion on the Statement is not modified in respect of the above matter.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.0001255)


Y.Lakshmi Nagarathnam

Partner

Membership Number: 212926



UDIN: 20212926AAAAET8343

Place: Secunderabad

Date: 12.11.2020

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar Society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@combatdrugs.in / info@decipherlabs.in , Ph: 040-48536100

Statement of Unaudited Standalone Financial Results For the Quarter and Half Year Ended 30th September, 2020

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year ended		Year ended
	30-09-2020	30-06-2020	30-09-2019	30-09-2020	30-09-2019	31-03-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	28.96	12.90	38.51	41.87	99.57	142.35
II. Other income	0.45	0.45	0.48	0.90	0.90	1.32
III.Total revenue (I + II)	29.42	13.35	38.99	42.77	100.47	143.67
IV. Expenses						
Purchase of Stock in trade	11.40	-	16.80	11.40	61.85	61.85
Changes in inventories of finished goods and stock in trade	0.30	1.31	(0.01)	1.61	0.28	0.28
Employee benefits expense	6.10	6.30	7.99	12.40	15.87	32.01
Finance Costs	0.51	0.30	-	0.81	-	-
Depreciation and Amortisation expense	0.91	0.88	0.06	1.79	0.12	0.35
Other expenses	5.74	3.02	4.52	8.76	10.04	32.43
Total expenses	24.96	11.80	29.36	36.77	88.16	126.92
V. Profit before tax (III - IV)	4.46	1.55	9.63	6.00	12.31	16.75
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.02)	0.05	0.01	0.03	0.01	(0.05)
VII. Profit/(Loss) for the period (V-VI)	4.49	1.50	9.62	5.97	12.30	16.80
VIII. Other comprehensive income	-	-	-	-	-	-
IX. Total comprehensive income for the year	4.49	1.50	9.62	5.97	12.30	16.80
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	1010.00	800.00	1010.00	800.00	1010.00
X. Earning per equity share						
(1) Basic	0.04	0.01	0.12	0.06	0.15	0.17
(2) Diluted	0.04	0.01	0.12	0.06	0.15	0.17

Notes

- The above results for the quarter ended 30 September 2020 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12th November, 2020. The Statutory Auditors carried out limited review and have expressed an unmodified opinion.
- The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- Due to the Covid 19 situation, there have been several restrictions imposed by the Governments across the globe considering public health and safety measures during March 2020. Based on the current indicators of economic conditions, the company expects to recover the carrying amount of all its assets. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the Company as at date of approval of these financial statements has used Internal and external sources of information including credit reports, related information and economic forecasts. The actual impact of the COVID-19 pandemic may be different from that estimated as at the date of approval of these standalone financial results and the company will continue to closely monitor any material changes to the economic conditions in the future.
- Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 12/11/2020

DECIPHER LABS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, BanjaraHills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@combatdrugs.in / info@decipherlabs.in , Ph: 040-48536100

Standalone Statement of Assets and Liabilities

Rs. in Lakhs

Particulars	As at 30 September 2020	As at 31 March 2020
	Unaudited	Audited
I. ASSETS		
Non-current assets		
(a) Property Plant and Equipment	27.91	10.83
(b) Financial assets		
Investments	841.00	841.00
(c) Deferred tax assets (net)		0.04
(c) Other non-current assets	0.30	0.30
Current assets		
(a) Inventories	30.26	31.87
(b) Financial assets		
(i) Trade receivables	23.89	17.45
(ii) Cash and cash equivalents	10.67	2.96
(iii) Other financial assets	-	0.52
(c) Current tax assets	0.06	0.06
(d) Other current assets	238.34	259.82
TOTAL ASSETS	1,172.43	1,164.85
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	1,010.00	1,010.00
(b) Other equity	102.48	96.51
Liabilities		
Non-current liabilities		
(a) Deferred tax liabilities (net)	0.06	-
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	26.96	23.04
(ii) Trade payables		
a) Total outstanding dues of Micro and small enterprises	-	-
b) Total outstanding dues of creditors other than Micro and small enterprises	24.19	25.59
(iii) Other financial liabilities	8.37	9.27
(b) Other current liabilities	0.37	0.44
TOTAL EQUITY AND LIABILITIES	1,172.43	1,164.85



For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

Place: Hyderabad

Date: 12/11/2020

DECIPHER LABS LIMITED (FORMERLY KNOWN AS COMBAT DRUGS LIMITED) (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society , Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.decipherlabs.in, email: info@combatdrugs.in / info@decipherlabs.in , Ph: 040-48536100

Statement of Cash Flow

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Half year ended 30th September, 2020 (Unaudited)		Year ended 31st March, 2020 (Audited)	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		6.00		16.75
Adjustments for :				
Depreciation		1.79		0.35
Operating Profit before Working Capital Changes		7.79		17.10
Adjustments for:				
(Increase) / Decrease in Trade Receivables	(6.44)		286.24	
(Increase) / Decrease in Inventories	1.61		0.28	
(Increase) / Decrease in Other Assets	21.98		(19.73)	
Increase / (Decrease) in Trade Payable	(1.40)		(287.81)	
Increase / (Decrease) in Other Liabilities	(0.88)		2.89	
		14.87		(18.13)
Cash Generated from Operations		22.66		(1.03)
Direct Taxes Paid		-		-
Net Cash generated from/(used in) Operating Activities		22.66		(1.03)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Property, Plant & Equipment	(18.87)		(10.50)	
Investments in Wholly Owned subsidiary Company			-	
Sale of Wholly Owned subsidiary Company	-		3.56	
Net Cash used in Investing Activities		(18.87)		(6.94)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Short Term Borrowings (net)	3.92		9.17	
Net Cash generated from Financing Activities		3.92		9.17
Net decrease in Cash and Cash Equivalents		7.72		1.20
Cash and Cash Equivalents at the beginning of the year		2.96		1.76
Cash and Cash Equivalents at the end of the year		10.67		2.96



Place: Hyderabad

Date: 12/11/2020

For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to
The Board of Directors
Decipher Labs Limited (Formerly known as Combat Drugs Limited)**

1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Decipher Labs Limited (Formerly known as Combat Drugs Limited) (the Company) for the quarter and half year ended 30th September, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.0001258)


Y.Lakshmi Nagaratnam
Partner

Membership Number:212926



UDIN: 20212926AAAAES9530

Place: Secunderabad
Date: 12.11.2020